Who are Dexmedetomidine and propofol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lidocaine with propofol, IV acetaminophen & IV propofol, Group D : Dexmedetomidine + propofol group, Fentanyl and Propofol, Regional analgesia and propofol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-and-propofol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexmedetomidine and propofol — Competitive Intelligence Brief

Dexmedetomidine and propofol (Dexmedetomidine and propofol) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-hypnotic combination. Area: Anesthesia and Sedation.

marketed Sedative-hypnotic combination Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol) Anesthesia and Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine and propofol (Dexmedetomidine and propofol) — Ain Shams University. Dexmedetomidine and propofol are combined sedative agents that work synergistically to produce sedation and anesthesia through alpha-2 adrenergic receptor agonism and GABA-A receptor potentiation, respectively.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexmedetomidine and propofol TARGET	Dexmedetomidine and propofol	Ain Shams University	marketed	Sedative-hypnotic combination	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
lidocaine with propofol	lidocaine with propofol	Imam Abdulrahman Bin Faisal University	marketed	Local anesthetic and sedative-hypnotic combination	Voltage-gated sodium channels (lidocaine); GABA-A receptors (propofol)
IV acetaminophen & IV propofol	IV acetaminophen & IV propofol	Beth Israel Deaconess Medical Center	marketed	Analgesic/antipyretic and sedative-hypnotic combination
Group D : Dexmedetomidine + propofol group	Group D : Dexmedetomidine + propofol group	Seoul National University Hospital	marketed	Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Fentanyl and Propofol	Fentanyl and Propofol	Jiangsu Hengrui Pharmaceutical Co., Ltd.	marketed	Opioid agonist + sedative-hypnotic combination	Mu opioid receptor (fentanyl); GABA-A receptor (propofol)
Regional analgesia and propofol	Regional analgesia and propofol	The Cleveland Clinic	phase 3	Local anesthetic + sedative-hypnotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-hypnotic combination class)

Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine and propofol — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-and-propofol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab